Amylin and the amylin receptors in migraine: Is there another pathway to target?
Cephalalgia · 2025-05 · 45 (5)
DOI: 10.1177/03331024251340066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cephalalgia, online erschienen am 19.05.2025. Verfasst von David Moreno-Ajona und 3 weiteren Autor:innen. Beteiligte Einrichtung: NIHR King's Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute o…. Hauptthemen laut MEDLINE: Migraine Disorders, Islet Amyloid Polypeptide, Receptors, Islet Amyloid Polypeptide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Here, we review the available evidence implicating amylin in migraine, its relationship with calcitonin gene-related peptide (CGRP) and its potential utility as a therapeutic target. The pathophysiology of migraine is currently better understood and the role of CGRP is key. Treatments targeting this pathway have been successful and migraine is a complex disorder, with so many molecules being implicated. Amylin, as for CGRP, is part of the calcitonin/CGRP peptide family. Some therapies intended to block the CGRP pathway can also target amylin receptors. Similar to CGRP, amylin can trigger migraine attacks in a provocation study. Amylin plasma levels have been highlighted as a potential migraine biomarker in one study in migraine patients. Moreover, some preclinical studies in rodents have also discussed sex differences. Comprehending the distinct and overlapping mechanisms between amylin and CGRP signalling could develop further our understanding of migraine pathophysiology. In summary, this review reveals, through initial studies, that targeting the amylin pathway may have a potential role as a novel treatment option for those who may not respond to other treatments, or as a better alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR King's Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College, Lon…
- Department of Neurology, Queen Elizabeth Hospital, London, UK.
- Department of Neurology, University of California, Los Angeles, CA, USA.
ORCID-Profile: David Moreno-Ajona, Jan Hoffmann, Peter J Goadsby
Zitieren
APA
Moreno-Ajona, D., Gosalia, H., Hoffmann, J., & Goadsby, P. J. (2025). Amylin and the amylin receptors in migraine: Is there another pathway to target?. Cephalalgia, 45(5). https://doi.org/10.1177/03331024251340066
Vancouver
Moreno-Ajona D, Gosalia H, Hoffmann J, Goadsby PJ. Amylin and the amylin receptors in migraine: Is there another pathway to target?. Cephalalgia. 2025;45(5). doi:10.1177/03331024251340066
BibTeX
@article{MorenoAjona2025,
author = {Moreno-Ajona, David and Gosalia, Helin and Hoffmann, Jan and Goadsby, Peter J},
title = {Amylin and the amylin receptors in migraine: Is there another pathway to target?},
journal = {Cephalalgia},
year = {2025},
volume = {45},
number = {5},
doi = {10.1177/03331024251340066}
}
EUVIMED